Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors
This study has been completed.
Study NCT00369109 Information provided by Barbara Ann Karmanos Cancer Institute
First Received on August 24, 2006. Last Updated on April 5, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Breast Cancer
Colorectal Cancer
Pancreatic Cancer
Additional conditions recognized in this trial
Breast Neoplasms
Colorectal Neoplasms
Pancreatic Neoplasms
More general conditions related to this trial
Breast Diseases
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Pancreatic Diseases
Rectal Diseases
Skin Diseases
Interventions listed in this trial
laboratory biomarker analysis
biopsy
Additional drug interventions recognized in this trial
Gemcitabine
Irinotecan
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Sponsors listed in this trial
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Back to top of Main Content
